Jason Shafrin, PhD

Healthcare Economist

Distributional Cost-Effectiveness Analysis: A Simple Example

02/09/2022

Jason Shafrin , PhD;

Jason Shafrin, PhD, describes 6 key steps to implementing distributional cost-effectiveness analysis.

Jason Shafrin, PhD, describes 6...

02/09/2022

Journal of Clinical Pathways

Counterpoint

Making Precision Benefit Design Patient-Centered

09/13/2018

Jason Shafrin , PhD;

Precision benefit design is an extension of the concept of value-based insurance design (VBID), which aims to link patient benefit design and coinsurance to the likely benefit of a treatment net of its cost. Whereas...

...

09/13/2018

Journal of Clinical Pathways

Healthcare Economist

Improving Care for Older Adults With Cancer

12/19/2019

Jason Shafrin , PhD;

Jason Shafrin, PhD, argues that more evidence, tools, and physicians with expertise in treating older patients with cancer are needed in order to provide safe and cost-effective treatments that meet patient priorities.

Jason Shafrin, PhD, argues that...

12/19/2019

Journal of Clinical Pathways

Healthcare Economist

Performance-Based Risk Sharing Agreements for Devices and Diagnostics

03/04/2022

Jason Shafrin , PhD;

Jason Shafrin, PhD, discusses a recent paper which reviewed publicly available data on performance-based risk sharing agreements for medical devices and diagnostics.

Jason Shafrin, PhD, discusses a...

03/04/2022

Journal of Clinical Pathways

We Have Vaccines, Now What? How to Ensure Continued COVID-19 Vaccine Discovery and Expedite Access

02/22/2021

Marlon Graf , PhD;

T. Joseph Mattingly II, PhD, PharmD, MBA;

Stacey Hickson , PhD;

Jason Shafrin , PhD;

Christoph Glaetzer , Dipl Kfm;

Rifat Tuly , MPH;

Abstract: The coronavirus disease 2019 (COVID-19) pandemic has resulted in a catastrophic burden in both health and economic costs. Despite the December 2020 emergency use authorizations of two COVID-19 vaccines,...

...

02/22/2021

Journal of Clinical Pathways

Healthcare Economist

How Should We Define “Unmet Need”?

12/23/2019

Jason Shafrin , PhD;

Jason Shafrin, PhD, sheds light on the challenge of quantifying the degree to which novel treatments address unmet need and how this would be reflected in different value frameworks.

Jason Shafrin, PhD, sheds light...

12/23/2019

Journal of Clinical Pathways

Healthcare Economist

Payer Perceptions of Genomic Precision Medicine

05/20/2020

Jason Shafrin , PhD;

Jason Shafrin, PhD, highlights a study that shows which factors payers consider when evaluating whether to provide coverage for genetic tests as well as how they value these factors.

Jason Shafrin, PhD, highlights a...

05/20/2020

Journal of Clinical Pathways

Healthcare Economist

Clinician-Directed Performance Improvement Is the Best Way to Improve Quality, So Why Won’t Payers Use It?

02/14/2020

Jason Shafrin , PhD;

Jason Shafrin, PhD, argues that clinician-directed performance improvement provides clear advantages, but payers are unlikely to be interested in this QI approach.

Jason Shafrin, PhD, argues that...

02/14/2020

Journal of Clinical Pathways

Healthcare Economist

Measuring the Value of Pharmaceuticals Over Time

02/27/2019

Jason Shafrin , PhD;

Jason Shafrin, PhD, explains the difficulty of measuring pharmaceutical value and notes ways in which ICER and IVI are attempting to address this challenge.

Jason Shafrin, PhD, explains the...

02/27/2019

Journal of Clinical Pathways

Healthcare Economist

Does a Drug’s Cost-Effectiveness Improve Over Time?

03/24/2020

Jason Shafrin , PhD;

Jason Shafrin, PhD, points to a recent study that shows clinical and cost effectiveness of a drug may improve over time; he asserts that this finding should be of importance to policymakers and payers.

Jason Shafrin, PhD, points to a...

03/24/2020

Journal of Clinical Pathways